Sandimmune

Heymann Nephritis, Lupus Nephritis, Nephrotic Syndrome + 30 more
Treatment
20 FDA approvals
20 Active Studies for Sandimmune

What is Sandimmune

CyclosporineThe Generic name of this drug
Treatment SummaryCyclosporine is a drug used to reduce the risk of organ transplant rejection and treat inflammatory and autoimmune conditions. It is derived from a fungus called Beauveria nivea and was originally developed by Sandoz, now known as Novartis. The FDA approved cyclosporine in 1983, and it is now available in several different forms.
Sandimmuneis the brand name
image of different drug pills on a surface
Sandimmune Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sandimmune
Cyclosporine
1983
68

Approved as Treatment by the FDA

Cyclosporine, also known as Sandimmune, is approved by the FDA for 20 uses which include Rheumatoid Arthritis and Prophylaxis against heart transplant rejection .
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
Prophylaxis against heart transplant rejection
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Kidney Transplantation
Glomerulosclerosis
Helps manage Glomerulosclerosis
Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
Therapeutic immunosuppression
Prophylaxis against graft versus host disease
Chronic Graft Versus Host Disease
Liver
Bone Marrow
Prophylaxis against stem cell transplant rejection
Patients who do not adequately respond to methotrexate alone
Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate
Steroid Resistant Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS)
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Heymann Nephritis
Helps manage Glomerulonephritis, Membranous
severe, recalcitrant Plaque psoriasis
Helps manage severe, recalcitrant Plaque psoriasis
Not responsive to other therapy
Helps manage Not responsive to other therapy
Transplantation
Bone Marrow Transplantation

Effectiveness

How Sandimmune Affects PatientsCyclosporine helps to prevent and control serious illnesses related to the immune system, like organ and bone marrow transplants, graft versus host disease, and autoimmune diseases. Common side effects of taking this drug include increased body hair, swollen gums, and high cholesterol. Some people also think that cyclosporine may cause damage to the kidneys.
How Sandimmune works in the bodyCyclosporine works by blocking inflammation in the body. It does this by binding to a receptor inside cells called cyclophilin-1. This stops a process called calcineurin, which normally causes inflammation by activating nuclear factor of activated T cells. This, in turn, stops the production of cytokines, which are proteins that cause inflammation. It also hinders the production of other factors related to T helper cell function. All of these effects work together to reduce inflammation in the body.

When to interrupt dosage

The prescribed measure of Sandimmune is contingent upon the diagnosed condition, including Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The amount of dosage fluctuates depending on the mode of delivery (e.g. Liquid - Intravenous or Ophthalmic; Topical) noted in the table underneath.
Condition
Dosage
Administration
Heymann Nephritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Glomerulosclerosis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
severe, recalcitrant Plaque psoriasis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Ulcerative Colitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Ulcerative Colitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Focal Segmental Glomerulosclerosis (FSGS)
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bulla
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Prophylaxis against stem cell transplant rejection
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Chronic Graft Versus Host Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Organ Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Patients who do not adequately respond to methotrexate alone
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Dry Eye Syndromes
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Lupus Nephritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Uveitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Kidney Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Ocular Rosacea
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical

Warnings

Sandimmune Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Psoriasis
Do Not Combine
Abnormal Renal Function
Do Not Combine
Hypertensive disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cyclosporine may interact with Pulse Frequency
There are 20 known major drug interactions with Sandimmune.
Common Sandimmune Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Aliskiren
Major
The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
Sandimmune Toxicity & Overdose RiskThe lowest toxic dose of cyclosporine in rats has been found to be 1480mg/kg, while the toxic dose in humans is 12mg/kg. In cases of overdose, it is recommended to induce vomiting and perform gastric lavage up to two hours after ingestion. There is limited information available on overdoses, but potential side effects include hepatotoxicity, nephrotoxicity, nausea, flushing, trembling, vertigo, vomiting, anorexia and feeling of increased body girth. These effects may last for up to two weeks. Dialysis and charcoal hemoperfusion are not effective methods for removing cycl
image of a doctor in a lab doing drug, clinical research

Sandimmune Novel Uses: Which Conditions Have a Clinical Trial Featuring Sandimmune?

81 active clinical trials are currently underway to assess the potential of Sandimmune in the management of Chronic Graft Versus Host Disease, Renal Pathologies and Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Prophylaxis against stem cell transplant rejection
0 Actively Recruiting
Excessive tearing
0 Actively Recruiting
Ocular Rosacea
1 Actively Recruiting
Phase 4
Organ Transplantation
0 Actively Recruiting
Dry Eye Syndromes
1 Actively Recruiting
Phase 3
Prophylaxis against graft versus host disease
0 Actively Recruiting
Glomerulosclerosis
0 Actively Recruiting
Steroid Resistant Nephrotic Syndrome
0 Actively Recruiting
Bone Marrow Transplantation
3 Actively Recruiting
Phase 3, Phase 2
Bone Marrow
0 Actively Recruiting
Heymann Nephritis
7 Actively Recruiting
Phase 2, Phase 3, Phase 1
Nephrotic Syndrome
11 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Prophylaxis against heart transplant rejection
0 Actively Recruiting
Bulla
0 Actively Recruiting
Juvenile arthritis
15 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable
Vernal Keratoconjunctivitis
0 Actively Recruiting
Transplantation
0 Actively Recruiting
Chronic Graft Versus Host Disease
29 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1
Liver
0 Actively Recruiting
severe, recalcitrant Plaque psoriasis
0 Actively Recruiting

Sandimmune Reviews: What are patients saying about Sandimmune?

5Patient Review
3/4/2009
Sandimmune for Prevent Kidney Transplant Rejection
5Patient Review
5/11/2010
Sandimmune for Prevent Kidney Transplant Rejection
I've been taking this medication for a long time and it's served me well.
3Patient Review
2/5/2011
Sandimmune for Severe Psoriasis that is Resistant to Treatment
I've been taking this medication for a little over a week now. Almost immediately after starting, I felt really terrible. Severe pain in my arm and headaches that were so bad they made me nauseous. I'm hoping the good effects will start to outweigh the bad soon.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sandimmune

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Sandimmune treat?

"Cyclosporine is an immunosuppressant typically used to prevent organ rejection after a transplant. It can also be used to treat severe psoriasis or rheumatoid arthritis."

Answered by AI

What is the generic name for Sandimmune?

"This medication is used to prevent organ rejection after a kidney, heart, or liver transplant. Cyclosporine belongs to a class of drugs called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Generic drugs usually cost less than the brand-name version. In some cases, they may not be available in every strength or form as the brand-name drug.

The oral capsule form of cyclosporine is available as the brand-name drugs Gengraf, Neoral, and Sandimmune, and as a generic drug. This medication is used to prevent organ rejection after a kidney, heart, or liver transplant. Cyclosporine belongs to a class of drugs called immunosuppressants, which work by weakening the body's defense system (immune system) to help the body accept the new organ as if it were its own. Generic drugs usually cost less than the brand-name versions of the same drug, although they may not be available in every strength or form."

Answered by AI

What drug class is Sandimmune?

"Nonribosomal peptides are usually synthesized by large multienzyme complexes.

Nonribosomal peptides are a type of peptide that is not made by a ribosome. They are found in bacteria, fungi, and other organisms. Nonribosomal peptides are made by large multienzyme complexes."

Answered by AI

What is the difference between Sandimmune and Neoral?

"The original formulation of Sandimmune mixes poorly with gastrointestinal fluids, resulting in low and inconsistent absorption. Neoral was developed to allow higher and more consistent absorption."

Answered by AI

Clinical Trials for Sandimmune

Have you considered Sandimmune clinical trials? We made a collection of clinical trials featuring Sandimmune, we think they might fit your search criteria.
Have you considered Sandimmune clinical trials? We made a collection of clinical trials featuring Sandimmune, we think they might fit your search criteria.
Have you considered Sandimmune clinical trials? We made a collection of clinical trials featuring Sandimmune, we think they might fit your search criteria.